Dublin-based Carrick Therapeutics Ltd. has licensed exclusive worldwide rights to develop and commercialize BTG945, now known as CT900, an investigational targeted ovarian cancer drug, from BTG PLC for an undisclosed sum.
CT900 combines targeting folate receptor α (FRα) and inhibiting thymidylate synthase. The small-molecule compound selectively enters cancer cells that over-express...